Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 11, 2023, at 10:30 a.m. PT, followed by a Q&A session at 10:50 a.m. PT. A live webcast will be available on the Company's website and can be replayed for 30 days post-event. Karyopharm is known for its SINE compound technology and its lead product, XPOVIO®, which is approved for various oncology indications. For more details, visit www.karyopharm.com.

Karyopharm Therapeutics (Nasdaq: KPTI) reported promising results from the Phase 1 study of selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. At week 24, 92% of efficacy-evaluable patients achieved ≥35% spleen volume reduction (SVR35), while 67% showed ≥50% symptom reduction (TSS50). Additionally, 57% of transfusion-independent patients stabilized their hemoglobin levels. The company aims to advance this combination therapy into randomized trials, highlighting its potential to improve current treatment standards.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced a webcast on December 12, 2022, to present updated Phase 1 study results on selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. Key opinion leaders, including Dr. Haris Ali and Dr. Srdan Verstovsek, will discuss data and the treatment landscape. The webcast will be accessible on the company's investor website. Karyopharm also has multiple presentations scheduled at the ASH 2022 Annual Meeting, focusing on its cancer therapies, particularly XPOVIO, which has various regulatory approvals worldwide.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has entered into a securities purchase agreement for a private placement expected to yield $165 million. The company will sell 31,791,908 shares of common stock at $5.19 per share, along with warrants for an additional 9,537,563 shares at an exercise price of $6.36. Proceeds will fund clinical development of selinexor and eltanexor, and general corporate purposes. The placement is set to close around December 7, 2022, pending standard conditions.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees as of November 30, 2022. The stock options have an exercise price of $5.29 per share, equivalent to Karyopharm's closing stock price on the grant date. Both stock options and RSUs will vest over four years, with specific conditions for early exercise tied to employment termination scenarios. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at facilitating recruitment.

Karyopharm Therapeutics (NASDAQ: KPTI), a leader in novel cancer therapies, announced its participation in two upcoming investor conferences in November 2022. The Jefferies 2022 London Healthcare Conference is scheduled for November 15, 2022, at 3:35 a.m. ET, featuring a fireside chat. The Piper Sandler 34th Annual Healthcare Conference will take place on November 29, 2022, at 11:30 a.m. ET, with a podium presentation. Webcasts of both events will be accessible for 90 days post-event on the company's investor webpage.

Karyopharm Therapeutics (KPTI) reported Q3 2022 total revenue of $36.1 million, with net product revenue from XPOVIO at $32.0 million, a 20% increase from Q3 2021. The company initiated a Phase 3 study for selinexor as maintenance therapy in advanced endometrial cancer. Encouraging data from a Phase 1 study of selinexor combined with ruxolitinib in myelofibrosis was highlighted, showing positive efficacy results. Karyopharm maintains its 2022 revenue guidance of $155 million to $165 million, emphasizing a cash runway into early 2024.

Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis. Preliminary efficacy showed 79% of patients achieved a ≥35% reduction in spleen volume at 12 weeks, with 86% at 24 weeks. The treatment also demonstrated significant symptom reduction in 69% of evaluable patients. Common adverse events were manageable, with no dose-limiting toxicities reported. Data on selinexor's effectiveness in triple-class refractory multiple myeloma will also be presented at the upcoming ASH Annual Meeting.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 23,200 shares and 16,000 restricted stock units (RSUs) to seven new employees as of October 31, 2022. These awards were made under the 2022 Inducement Stock Incentive Plan as an incentive for new hires in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $4.76 per share and will vest over four years, while RSUs will also vest over the same period. Both awards include conditions related to employment status and change in control provisions.